Gemtuzumab - CISMeF

Preferred Label : Gemtuzumab;

MeSH definition : Immunotoxin that consists of an anti-CD33 (CD33 ANTIGEN) monoclonal antibody conjugated to CALICHEAMICIN. It is used for the treatment of ACUTE MYELOID LEUKEMIA.;

MeSH hyponym : Gemtuzumab-Ozogamicin; CMA-676; CMA676;

MeSH Related Number : 8GZG754X6M;

UNII : 93NS566KF7;

Details

Origin ID

D000079982;

UMLS CUI

C0872968;

ATC code(s)
- gemtuzumab ozogamicin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Gemtuzumab [NCIt concept]
- Gemtuzumab [SMS substance]
Pharmacological action(s)
- Antineoplastic Agents, Immunological [MeSH Descriptor]
- immunologic factors [MeSH Descriptor]
- immunotoxins [MeSH Descriptor]
Record concept(s)
- CMA 676 [MeSH concept]
- gemtuzumab [MeSH concept]
- gemtuzumab ozogamicin [MeSH concept]
- mylotarg [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Gemtuzumab [NCIt concept]
Validated automatic mappings to BTNT
- Gemtuzumab Ozogamicin [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients